Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.


Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations


I. Otsuka, M. Uno, A. Wakabayashi, S. Kameda, H. Udagawa and T. Kubota, “Predictive Factors for Prolonged Survival in Recurrent Endometrial Carcinoma: Implications for Follow-Up Protocol,” Gynecologic Oncology, Vol. 119, No. 3, pp. 506-510. doi:10.1016/j.ygyno.2010.08.013

has been cited by the following article:

  • TITLE: Patterns of Recurrence and Their Significance in Patients with Endometrial Carcinoma—For Improved Follow-Up after Initial Treatment

    AUTHORS: Fumi Utsumi, Hiroaki Kajiyama, Kiyosumi Shibata, Hiroko Mitsui, Ryuichiro Sekiya, Mika Mizuno, Shiro Suzuki, Tomokazu Umezu, Eiko Yamamoto, Fumitaka Kikkawa

    KEYWORDS: Endometrial Carcinoma; Recurrence Site; Postrecurrence Survival; Symptomatic; Vaginal Vault Cytology

    JOURNAL NAME: Surgical Science, Vol.4 No.2, February 19, 2013

    ABSTRACT: Objectives: The aim of this study was to identify the patterns of recurrence and their significance in patients with endometrial carcinoma (EMCA). Patients and Methods: After a search of the medical records from single institutions, a total of 49 patients with relapsed endometrial carcinoma were retrospectively evaluated. Various clinical information was examined, including the site of recurrence, detection procedure, and presence or absence of any symptom at the time of recurrence. Furthermore, the postrecurrence survival analysis was based on the Kaplan-Meier method. Results: The median follow-up period of all patients was 39.4 months (5.8 - 293.1). In all, twenty-five (51.0%) patients experienced recurrence within 12 months after the final treatment. At the time of recurrence, 15 (30.6%) and 34 (69.4%) patients were symptomatic and asymptomatic, respectively. Among the 34 asymptomatic patients, recurrence was detected by CT scan in 14 (28.6%), tumor markers alone in 14 (28.6%), and pelvic examination/ultrasound scan in 5 (10.2%). There was no relapsed case detected by vaginal vault cytology alone. The 5-year postrecurrence survival rates in symptomatic and asymptomatic patients were 57.5 and 36.6 months, respectively (P = 0.2973). After recurrence, 12 patients underwent debulking surgery, and 37 received salvage chemotherapy or radiotherapy. The postrecurrence survival of patients receiving surgery did not differ from that of those with chemotherapy/radiotherapy (P = 0.9198). Conclusion: Although imaging studies and tumor marker measurement contributed to the early detection of recurrence, they did not necessarily improve the prognosis postrecurrence.